Clinical trial
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m…
NCT00136604 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00136604 |
|---|---|
| Title | Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m |
| Official title | Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Diphtheria, Tetanus, Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin |
| Intervention type | Biological |
| Interventions | Tritanrix-HepB/Hib-MenAC, Mencevax ACWY, Tritanrix-HepB/Hiberix, Meningitec |
| Enrollment | 617 |
| Start date | Jan 22, 2006 |
| Primary completion | Apr 23, 2006 |
| Completion | Apr 23, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Feb 20, 2020 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: